Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026GlobeNewsWire · 2 days ago
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High – Still a Buy?Defense World · 3 days ago
10,232 Shares of Kiniksa Pharmaceuticals International, plc $KNSA Acquired by B. Riley Wealth Advisors Inc.Defense World · Oct 16, 2026
Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM)Defense World · Oct 16, 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Consensus Price Target of $87.38 According to BrokeragesDefense World · Sep 25, 2026
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's WhyZacks Investment Research · Sep 17, 2026Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 28, 2026 | $0.30 | $0.30 | Beat |
| Apr 28, 2026 | $0.18 | $0.27 | Beat |
| Feb 24, 2026 | $0.29 | $0.17 | Miss |
| Oct 28, 2025 | $0.33 | $0.23 | Miss |
| Jul 29, 2025 | $0.18 | $0.23 | Beat |
| Apr 29, 2025 | $0.02 | $0.11 | Beat |